"The most potent drug ever developed for breast cancer”

Enhertu results could shift the way physicians treat hormone receptor-positive, metastatic breast cancer

June 4, 2024 Check out STAT+

Sponsored By

ADAM FEUERSTEIN/STAT STAT+ | With new results at ASCO, Enhertu once again rewrites rules of breast cancer treatment Enhertu stalled the growth of tumors by more than a year in women with the most common form of metastatic breast cancer. By Adam Feuerstein Palliative care for cancer patients is found to be as effective given virtually as in person A seven-year study found that telehealth sessions helped people with advanced cancer deal with symptom management and emotional needs. By Angus Chen STAT+ | ASCO 2024: FDA oncology head wants clinical trials to range beyond China alone At an ASCO 2024 event, Richard Pazdur, the FDA's top oncologist, said the agency wants to see companies conducting studies across the world. By Elaine Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser